The day after COVID-19 in IBD: how to go back to ‘normal’

Silvio Danese; Bruce Sands; Siew C. Ng; Laurent Peyrin-Biroulet

doi:10.1038/s41575-020-0322-8

The day after COVID-19 in IBD: how to go back to ‘normal’

Silvio Danese, Bruce Sands, Siew C. Ng, Laurent Peyrin-Biroulet

Research output: Contribution to journal › Comment/debate

14 Scopus citations

Original language	English
Pages (from-to)	441-443
Number of pages	3
Journal	Nature Reviews Gastroenterology and Hepatology
Volume	17
Issue number	8
DOIs	https://doi.org/10.1038/s41575-020-0322-8
State	Published - 1 Aug 2020

Access to Document

10.1038/s41575-020-0322-8

Cite this

@article{8f29a4f71f8449739eb524116a7cac20,

title = "The day after COVID-19 in IBD: how to go back to {\textquoteleft}normal{\textquoteright}",

author = "Silvio Danese and Bruce Sands and Ng, \{Siew C.\} and Laurent Peyrin-Biroulet",

note = "Funding Information: S.D. has served as a speaker, consultant and an advisory board member for Abbvie, Ferring, Hospira, Johnson \& Johnson, Merck, Millennium Takeda, Mundipharma, Pfizer, Tigenix, UCB Pharma and Vifor. B.S. has received financial support for research: Janssen, Takeda; consultancy: 4D Pharma, Abbvie, Allergan, Amgen, Arena Pharmaceuticals, Boehringer-Ingelheim, Capella Bioscience, Celgene, Celltrion Healthcare Co. Ltd., Ferring, Janssen, Lilly, Otsuka, Palatin Technologies, Pfizer, Progenity, Protagonist Therapeutics, Rheos Medicines, Salix Pharmaceuticals, Seres Therapeutics, Sienna Biopharmaceuticals, Takeda, Target PharmaSolutions, Therevance Biopharma R\&D and Vivelix Pharmaceuticals. S.C.N. has served as speaker for Janssen, Abbvie, Tillotts, Takeda, Olympus, Ferring. L.P.-B. has received consulting fees: Merck, AbbVie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillotts, Vifor, Therakos, Pharmacosmos, Pil{\`e}ge, BMS, UCB Pharma, Hospira, Celltrion, Takeda, Biogaran, Boerhinger Ingelheim, Lilly, Pfizer, HAC-Pharma, Index Pharmaceuticals, Amgen and Sandoz; lecture fees: Merck, AbbVie, Takeda, Janssen, Takeda, Ferring, Norgine, Tillots, Vifor, Therakos, Mitsubishi and HAC-Pharma.",

year = "2020",

month = aug,

day = "1",

doi = "10.1038/s41575-020-0322-8",

language = "English",

volume = "17",

pages = "441--443",

journal = "Nature Reviews Gastroenterology and Hepatology",

issn = "1759-5045",

publisher = "Nature Research",

number = "8",

}

TY - JOUR

T1 - The day after COVID-19 in IBD

T2 - how to go back to ‘normal’

AU - Danese, Silvio

AU - Sands, Bruce

AU - Ng, Siew C.

AU - Peyrin-Biroulet, Laurent

N1 - Funding Information: S.D. has served as a speaker, consultant and an advisory board member for Abbvie, Ferring, Hospira, Johnson & Johnson, Merck, Millennium Takeda, Mundipharma, Pfizer, Tigenix, UCB Pharma and Vifor. B.S. has received financial support for research: Janssen, Takeda; consultancy: 4D Pharma, Abbvie, Allergan, Amgen, Arena Pharmaceuticals, Boehringer-Ingelheim, Capella Bioscience, Celgene, Celltrion Healthcare Co. Ltd., Ferring, Janssen, Lilly, Otsuka, Palatin Technologies, Pfizer, Progenity, Protagonist Therapeutics, Rheos Medicines, Salix Pharmaceuticals, Seres Therapeutics, Sienna Biopharmaceuticals, Takeda, Target PharmaSolutions, Therevance Biopharma R&D and Vivelix Pharmaceuticals. S.C.N. has served as speaker for Janssen, Abbvie, Tillotts, Takeda, Olympus, Ferring. L.P.-B. has received consulting fees: Merck, AbbVie, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillotts, Vifor, Therakos, Pharmacosmos, Pilège, BMS, UCB Pharma, Hospira, Celltrion, Takeda, Biogaran, Boerhinger Ingelheim, Lilly, Pfizer, HAC-Pharma, Index Pharmaceuticals, Amgen and Sandoz; lecture fees: Merck, AbbVie, Takeda, Janssen, Takeda, Ferring, Norgine, Tillots, Vifor, Therakos, Mitsubishi and HAC-Pharma.

PY - 2020/8/1

Y1 - 2020/8/1

UR - https://www.scopus.com/pages/publications/85085884641

U2 - 10.1038/s41575-020-0322-8

DO - 10.1038/s41575-020-0322-8

M3 - Comment/debate

C2 - 32483356

AN - SCOPUS:85085884641

SN - 1759-5045

VL - 17

SP - 441

EP - 443

JO - Nature Reviews Gastroenterology and Hepatology

JF - Nature Reviews Gastroenterology and Hepatology

IS - 8

ER -